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Context: Subjects with Type 2 Diabetes Mellitus (T2DM) and diabetic nephropathy (DN) often
exhibit hypertriglyceridemia. The mechanism(s) of such an increase are poorly known.
Objective:We investigated VLDL-Apo B 100 kinetics in T2DM subjects with and without DN, and
in healthy controls.
Design: Stable isotope 13C-leucine infusion, and modelling analysis of tracer-to-tracee ratio dy-
namics in the protein product pool in the 6–8 hr period following tracer infusion, were employed.
Setting:Male subjects affected by T2DM, eitherwith (n9) orwithout (n5) DN, and healthymale
controls (n6), were studied under spontaneous glycemic levels in the post-absorptive state.
Results: In the T2DM patients with DN, plasma triglyceride (TG) (2.20.8 mmol/L, MeanSD) and
VLDL-Apo B 100 (17.410.4 mg/dl) concentrations, and VLDL-Apo B 100 pool (0.560.29 g), were
60–80% greater (p0.05 or less) than those of the T2DM subjects without DN (TG: 1.40.5
mmol/L; VLDL-Apo B 100: 9.92.5 mg/dl; VLDL-Apo B 100 pool: 0.360.09 g), and 80–110%
greater (p0.04 or less) than those of nondiabetic controls (TG: 1.20.4 mmol/L; VLDL-Apo B 100:
8.21.7mg/dl; VLDL-ApoB100: 0.320.09g). In sharp contrast however, in the subjectswithT2DM
and DN, VLDL-Apo B 100 FSR was 50% lower (4.82.2 pools/day) than that of either the T2DM
subjects without DN (9.94.3 pools/day, p0.025) or the control subjects (12.59.1 pools/day,
p0.04).
Conclusions: The hypertriglyceridemia of T2DM patients with DN is not due to hepatic VLDL-Apo
B 100 overproduction, which is decreased, but it should be attributed to decreased apolipoprotein
removal.
Diabetic nephropathy (DN) in type 2DiabetesMellitus(T2DM) is frequently associated with albuminuria,
increased concentrations of triglycerides, VLDL-Apo B
100, and fibrinogen, and normal or reduced plasma albu-
min concentrations (1–3).We have previously shown that
inT2DMwithDN,both fibrinogenandalbumin synthesis
are increased (4), the former suggesting a primary defect
contributing to the hyperfibrinogenemia (5), likely asso-
ciated to insulin-resistance (6), the latter unveiling a pos-
sible compensatory mechanism for the urinary albumin
loss.
The apolipoprotein Apo B 100, fibrinogen and albu-
min, are three liver-secreted proteins. Whether VLDL-
Apo B 100 synthesis is also increased in T2DMwith DN,
similarly to that of albumin and fibrinogen, thus account-
ing for the increased circulating concentrations of VLDL-
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Apo B 100 (and triglycerides), has not been established. In
previous studies of apolipoprotein kinetics in T2DM,
VLDL production was found to be either increased (7) or
normal (8). In these studies however, the diabetic subjects
were not characterized as regards presence or absence of
nephropathy.
The interest into the regulatory mechanisms of these
three liver-synthesizedproteins arises also fromtheknown
association between increased concentrations of triglyc-
erides, VLDL-Apo B 100 and fibrinogen, as well as of
urinary albumin excretion, with cardiovascular diseases
(9–11).
The apolipoprotein Apo B 100 is a component of both
the VLDLs and LDLs. VLDLs predominantly carry circu-
lating triglycerides, whereas LDLs predominantly bind
cholesterol and small amounts of triglycerides (12,
13).The study of apolipoprotein kinetics is therefore rel-
evant also with respect to the understading of the mech-
anisms of the synthesis by the liver of important cardio-
vascular risk factors.
Therefore, the aim of this study was to measure, in
patients affected by T2DM,DNand albuminuria, the rate
of VLDL-Apo B 100 synthesis/production, using a leu-
cine-based isotope-dilution method and modeling
analysis.
Materials and Methods
Isotope
The L-[1-13C]leucine ([13C]Leu) stable isotope was pur-
chased from Tracer Technologies (Masstrace, Woburn, MA,
USA), dissolved in sterile saline under aseptic conditions before
use, filtered through a 0.2 filter (Millipore, France) and proven
to be sterile and pyrogen-free before use.
Patients
Nine male subjects affected by T2DM and DN (here defined
as T2DM DN), five T2DM subjects without DN (defined as
T2DMDN-), and six male healthy controls, were recruited. The
studies were initiated in 1996 and completed in 20101. The pro-
tocol was approved by the Ethical Committee of the Medical
Faculty at the University of Padova, Italy, and was performed
according to the Helsinki Declaration (1983), as amended in
2008. In the T2DM subjects, DN was diagnosed from an in-
creased albumin excretion rate (AER,30mg/d) on the basis of
at least two 24-hour determinations, in the absence of other
clinical, biochemical and instrumental causes of albuminuria.
Threeof theT2DMDNweremicroalbuminuric (AERbetween
30–300 mg/d), while six were macro-albuminuric (AER: 300
mg/d). Sixof theT2DMDN subjects alsohad increasedplasma
creatinine concentrations (115 mol/L) (one to 119 mol/L,
four between 135 and 210 mol/L, the latter to 331 mol/L).
The clinical and biochemical characteristics of the subjects
withT2DMand the controls are reportedonTable1.TheT2DM
DN subjects were modestly older (by 11 and 14 yrs respec-
tively) and heavier (by 8 and 13% respectively) than either
the T2DMDN- or the non diabetic controls. The overall differ-
ences among the three groups were however not significant (p
value  0.07 by ANOVA). All subjects had been adapted to a
standard weight-maintaining diet containing 50% calories as
carbohydrates,20% proteins and30% lipids. Daily protein
intake was  0.8 g/Kg of body weight, unrestricted in all the
control and the subjects with T2DM, either without or with
microalbuminuria, whereas it was recommended to be at least
0.6 g/Kg of body weight in the T2DM subjects with macroalbu-
minuria. The antidiabetic therapy in the T2DM DN subjects
Table 1. Clinical and metabolic parameters of the
T2DM with albuminuria, and control subjects studied.
MeansSD
Parameter T2DM DN T2DM DN- Controls
Number 9 5 6
Age (years) 56  8 45  10 42  17
BMI (kg/
m2)
31.2  4.5 28.9  3.5 27.7  5.9
Diabetes
duration
(years)
19  10 14  6 /
Glucose
(mmol/
liter)
12.3  4.0 b 9.5  2.9 f 5.1  0.4
Insulin
(nmol/
liter)
111  24 106  45 82  12
HbA1c
(mmol/
mmol)
87  16 b, d 86  24 f 35  3
Total
Cholesterol
(mmol/
liter)
5.36  0.97 4.60  0.76 4.59  0.32
HDL
Cholesterol
(mmol/
liter)
0.86  0.42 1.09  0.26 1.24  0.39
LDL
Cholesterol
(mmol/
liter)
3.68  1.54 3.44  0.96 3.29  0.49
Triglyceride
(mmol/
liter)
2.19  0.83
b, c
1.40  0.51 1.22  0.42
VLDL Apo
B (mg/dl)
17.36  10.36
a, c
8.44  1.41 8.20  1.70
Albumin
(g(L)
37.6  4.9 40.5  2.5 40.7  1.9
Fibrinogen
(g/liter)
4.9  1.4 b, d 3.1  1.0 2.4  0.4
Creatinine
(mol/
liter)
159  76 b, d 77  14 77  9
a: P  0.05, T2DM DN vs. Controls; b: P  0.025 or less, T2DM DN
vs. Controls;
c P  0.05, T2DM DN vs. T2DM DN-; d P  0.025 or less, T2DM
DN vs. T2DM DN-
e P  0.05, T2DM DN- vs. C; f P  0.025 or less, T2DM DN- vs. C
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consisted, besides diet, of oral hypoglycaemic agents (OHA, n
2), insulin (n  3), or combinations of the two (n  4). Four of
the T2DM DN- subjects were treated with OHA, and one with
a combination ofOHA and insulin. Three T2DMDN subjects
were also treated with hypolipidemic agents (fibrates). Most of
the diabetic patients were taking antihypertensive agents, often
in combinations (ACE-inhibitors: n  7; furosemide: n  6;
hydrochlorotiazide: n  1; calcium antagonists: n  9; beta or
-blockers: n 5; clonidine: n 1). Five diabetic patients were
treated with ticlodipine, one with aspirin. No drug was assumed
by any of the control subjects.
Experimental design
On themorning of the study, all subjects were admitted at the
Clinical Study Unit of the Metabolism Division of the Padova
University Hospital, at 07:00 A.M. A polyethylene catheter was
inserted into a dorsal vein of the hand, which was maintained in
a plexigas box heated at 55°C, to obtain arterialized-venous
blood samples. A second catheter was placed into an antecubital
vein of the opposite arm, and used for isotope and dye infusions
(see below). Blood samples were taken before the start of the
infusions, to determine the baseline natural enrichments of
plasma [13C]Leu, [13C]-ketoisocaproate [13C-KIC], and
VLDL-Apo B 100 [13C]Leu.
Thereafter, a primed- (0.6 mol x kg-1), continuous infusion
of [13C]Leu (at the rate of 0.01mol x kg-1 xmin-1) was started,
and continued throughout the study using a calibrated pump
(Harvard Apparatus, South Natick, MA, USA). Eight ml of
whole blood samples were then collected at 30, 45, 60, 90,
120, 150, 180, 210 and 240, and subsequently 60-minute
apart between 240-480, for the isolation of VLDL-Apo B 100.
Additional 5 ml of blood samples were collected at frequent
intervals between120and480, for thedeterminationofplasma
substrate, isotope and hormone concentrations. In half of the
healthy control subjects the isotope infusion was completed at
360, since in the first three subjects studied for 480 the steady
state of the VLDL-Apo B 100 [13C]Leu had been attainedwithin
the sixth hour.
Plasma volume was calculated from the distribution space of
the dye Cardiogreen (14) (Infracyanine, SERB, Paris, France).
Briefly, 25 mg of the dye was dissolved in 10 ml of 5% glucose
solution and2mlof 20%humanalbumin shortly before use, and
rapidly injected within 10 seconds during the first hour of the
[13C]Leu infusion, after a brief local reactive hyperemia, ob-
tained by venous stasis, to enhance the systemic delivery of the
dye. Plasma sampleswere taken before and at 1, 2, 3, 4, 5, 7,
10 and 20 after the injection. Dye concentration in the infusate
aswell as in plasma, after proper dilutions,was determined spec-
trophotometrically at 805 . The best fit for a straight line was
usually obtained between the 1 and the 7-10min samples. The
intercept of this line in the y axis corresponded to the dye’s initial
space of distribution (ie, plasma volume).
Analytical methods
Standard biochemical analyses. Plasma glucose, insulin, gly-
cated hemoglobin (HbA1c), triglycerides, total and HDL cho-
lesterol, creatinine, albumin and fibrinogen concentrations, and
daily urinary albumin excretion, were assessed by standard lab-
oratory methods. LDL cholesterol was calculated using the
Friedwald’s formula.
Isolation of VLDL-Apo B 100, and 13C-Leucine
analysis
The lipoproteins were separated from 4 ml plasma by means
of standard procedures of preparative sequential ultracentrifu-
gation (15) using a L5–65 ultracentrifuge (Beckman Instru-
ments, Fullerton, CA, USA) and a Ti 50.3 rotor, at densities of
1.006, 1.063 and 1.21 g/mL. The former fraction, containing the
VLDLs,wasused for further analysis2. Theprotein content of the
samples was quantified by the Lowry assay (16). The concen-
trations of Apo B 100 in the VLDL samples were determined by
ELISA (17).
Thereafter, the VLDL fractions were delipidated as described
elsewhere (18), then isolated fromother proteins (mainly Apo E)
using a 3.5%–10% gradient of SDS-PAGE (19), and stained by
the Coomassie-Blue. A single band was recovered in correspon-
dence of the theoretical Apo B 100 molecular size, which was
further confirmed against commercially-available standard mo-
lecularmarkers. The bandswere excised out of the gel, sliced and
acid-hydrolyzed for 24 hours. The VLDL-Apo B 100-derived
free leucine was then purified using cation exchange chroma-
tography. The leucine and -ketoisocaproate (KIC) in plasma
were isolated as previously described (18), and their [13C]-en-
richment, aswell as that of [13C]-leucine in theVLDL-ApoB100
protein-derived hydrolysate, were determined as t-butyldimeth-
ylsilyl derivatives by Gas Chromatography-Mass Spectrometry
(GCMS) (20), using a Hewlett-Packard GCMS (model 5973), a
capillary column and electron impact ionization. Enrichments
were expressed as tracer to tracee ratios by using published for-
mulas (21).
Calculations and modeling
The Apo B-100 leucine kinetics in the VLDLs were analyzed
using the monoexponential solution of a precursor-product
model (22) (see also: Additional data), ie, by assuming that the
precursor, that is intracellular [13C]-leucine, rapidly reaches a
steady-state condition after the primed continuous infusion.
The tracer incorporation into the product can be
described by the following equation:
	Eq.1

where: “z(t)” represents the time course of the tracer-to-tracee
(TTR) ratio of [13C]-Leu in the VLDL-Apo B-100 protein prod-
uct pool; “A” is the TTR of the precursor pool, which was that
of 13C-Leucine TTR estimated at “plateau” in the VLDL-Apo B
100; “FSR” (min-1) indicates the Fractional Synthesis Rate of
VLDL-Apo B 100, which is equal to its fractional turnover since
the system was at steady state throughout the experiment; and
“” (min) is the delay of tracer appearance into the product pool.
Notably, the 13C-Leucine TTR estimated at “plateau” in the
VLDL-Apo B 100 was very close to that of plasma 13C- -ke-
toisocaproate (KIC).
The model parameters A, FSR, and , and their precision,
were estimated in each individual by applying a weighed least-
squares method implemented in MATLAB to the VLDL TTR
data. Weights were chosen optimally, ie, equal to the inverse of
the measurement errors. They were assumed to be Gaussian,
independent, zero-mean and with a constant standard deviation
which was estimated a posteriori. (see also: “Additional data”).
The absolute secretion rate (ASR, expressed in g x day-1) of
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VLDL-Apo B 100 was calculated by multiplying FSR times the
plasma (ie, intravascular) protein pool of the protein, on turn
calculated from the product of VLDL-Apo B 100 concentrations
and the intravascular (ie, plasma) volume, determined from dye
bolus-injection data.
Statistical analysis
The data are expressed asMeanSD. The differences among
the groups were analized by the One Way Analysis of Variance
(ANOVA) and the Fisher’s post hoc test. A p value less than 0.05
was considered as statistically significant.
Power calculation, based on an a priori assumed difference
between groups’ means of 40%, an estimated SD (the average
value of SDs found in previous studies on VLDL-Apo B kinetics,
ie, refs #7, #8, and 24#) of 30%of themeans, an average number
of subjects of5 for each group (in our hands they actuallywere:
5, 6 and 9), and setting alpha at 0.05, yielded a power of 80%,
therefore sufficient to detect significant differences among the
subjects’ groups.
Results
Substrate, hormone and isotope concentrations
The T2DM subjects exhibited greater glucose and
HbA1c levels than the control subjects, whereas plasma
insulin concentrations were slightly although not signifi-
cantly greater than control values (Table 1). Plasma tri-
glyceride, VLDL-Apo B 100, fibrinogen and creatinine
concentrations (Table 1) were elevated only in the T2DM
DN subjects, whereas HDL cholesterol tended to be
lower (although insignificantly) in this than in the two
other groups. Total and LDL-cholesterol, and albumin
concentrations were not different among the groups.
In the T2DM DN subjects, the [13C]-Leucine TTR
estimated at plateau in theVLDL-ApoB100 fraction,was
30% greater (albeit unsignificantly) than that of both
the T2DM DN- and the non diabetic subjects (Table 2).
VLDL-Apo B 100 kinetics
The monoexponential model (Eq. 1) resulted to be an
adequate description of VLDL-Apo B 100 kinetics, since
it was able to fit the TTR data in all our subjects (Figure
1), and its parameters A, FSR, and  were estimated with
acceptable precision (Table 2) (see also: Additional data).
In theT2DMDN subjects, theVLDL-ApoB100pool
size was80% greater than that of the two other groups
(Figure 2, top). In sharp contrast however, VLDL-Apo B
100FSR (ie, thenumberof proteinpools turnedover in the
unit of time), expressed either as min-1 (Table 2), or as
day-1 (Figure 2, middle panel), was 50%-60% lower
than that calculated in both the T2DMDN- and the con-
trol subjects. Thedelay in appearanceofVLDL-ApoB100
into the plasma pool was not different among the groups
(Table 2). In the T2DMDN subjects, VLDL-Apo B 100
ASR (Figure 2, bottom panel) was35% lower than that
of the non diabetic controls, whereas in the T2DM DN-
subjects it exhibited somewhat intermediate values, with-
out however significant differences among the groups.
Discussion
In this study we show that, in subjects affected by T2DM,
diabetic nephropathy and albuminuria, the increased
VLDL-Apo B 100 and triglyceride concentrations are not
due to an increased VLDL-Apo B 100 fractional synthesis
rate, which is rather significantly decreased, with respect
to that of both the nondiabetic controls and subjects with
T2DM but without nephropathy. Therefore, under the
steady-state conditions of this study, the only reasonable
explanation for the increased VLDL-Apo B 100 concen-
tration in T2DM subjects with nephropathy is a reduced
Apo B 100 removal from plasma.
Our results should be discussed in the context of pre-
vious reports investigating Apo B kinetics in T2DM sub-
jects, as well as of the possibile cause(s) for the discrep-
ancies between our and other studies. In the study by
Duvillard et al (7), an increased VLDL Apo B 100 pro-
duction was reported in patients with T2DM. However,
there are remarkable differences in subjects’ characteris-
tics between that and our study. In the referenced report
(7) only six patients with T2DM were studied, they were
of both sexes and obese, whereas their non diabetic con-
trols were lean. In the subjects with diabetes, the fasting
triglyceride concentrations were markedly increased
(by  5 fold vs. controls), their metabolic control was
remarkedly poor (HbA1c: 9.3%); and the isotopic study
Table 2. Parameters for the calculation of VLDL-Apo B kinetics in the T2DM and control subjects. Values are
expressed as MeanSD Values within brackets indicate the precision of the estimates, as coefficient of variation.
Parameter T2DM DN T2DM DN- Controls
13C-Leu TTR (estimated
at plateau)
0.099  0.027 (31%) 0.077  0.019 (19%) 0.072  0.051 (20%)
VLDL-Apo B FSR (min-1) 0.0033  0.0016 a, b (51%) 0.0069  0.0030 (39%) 0.0087  0.0063 (42%)
VLDL-Apo B delay (min) 22.3  13.5 (55%) 31.9  16.6 (63%) 24.4  16.1 (52%)
a: P  0.025 T2DM DN vs. Controls; b: P  0.05 T2DM DN vs. T2DM DN-
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was performed in the fed state. No data on renal function
and albuminuria was reported (7).
In the studybyMalmströmet al (8), near-normalVLDL
ApoB100production rateswere reported in subjectswith
T2DM. The subjects with diabetes and the controls there
studied were fairly well matched. In the group with dia-
betes (n  6), metabolic control was modestly impaired,
triglyceride concentrationswere increasedbyonly30%,
and the VLDL-Apo B 100 pool size was normal. That
study (8) was performed employing an isotopic method
different from ours, ie, using a leucine-tracer bolus injec-
tion and a multicompartmental approach for the kinetic
analysis. A separate analysis of the VLDL1-and VLDL2
Apo B particles was performed. Furthermore, the study
was carried out under both hyperglycemic, hyperinsuline-
mic-hyperglycemic, and hyperinsulinemic-euglycemic
conditions. In the hyperglycemic state (a condition com-
parable to ours), a normalVLDL1-ApoB, and a decreased
VLDL2-ApoB synthesiswere reported in the subjectswith
T2DM,whereas the fractional catabolic rate of these apo-
lipoproteins was slightly decreased in T2DM. No data on
the renal status of subjects with diabetes were reported in
this study either (8).
In our study, we did not determine the size of theVLDL
particles, which are known to be small and dense in pa-
tients with T2DM and nephropathy, and associated to
hypertriglyceridemia (23).VLDLparticles of different size
were previously shown to exhibit different kinetic features
(8). Whether and to which extent these methodological
differences may contribute to the observed discrepancies
between previous and the present data, remains to be
established.
Interestingly however, in agreement with our findings,
also in nondiabetic, nephrotic syndromes (thus exhibiting
clinical proteinuria), VLDL-Apo B 100 concentrations
were increased whereas their fractional synthesis rates
were decreased (24, 25), indirectly suggesting a decreased
VLDL-Apo B 100 catabolism as the cause for the hyper-
triglyceridemia of these subjects. Thus, albuminuria, in
either type 2 Diabetes or in non diabetic proteinuric syn-
dromes, seems to carry some specific features associated to
a decreased VLDL removal.
Aspotential explanationsof suchanhypothesis, several
factors should be taken into account. A decreased activity
and/or a reduced mass of the lipoprotein lipase (the en-
zyme removing circulating triglycerides fromplasma), had
been previously described in diabetic nephropathy (26).
This hypothesis was supported also by a greater triglyc-
eride response after anoral fat load in subjectswithT2DM
nephropathy than in thosewithout nephropathy (26). Ge-
Figure 1. Ability of the monoexponential model (dashed line) to
reproduce the VLDL-Apo B 100 tracer-to-tracee data (diamonds) in
T2DM-DN (upper panel), T2DM-DN (middle panel) and Controls
(lower panel). Average data vs average model fit are shown.
Figure 2. VLDL-Apo B 100 pool (in mg; top panel), fractional
synthesis rate (FSR, expressed as day-1; middle panel) and absolute
synthesis rate (ASR, in g x day-1; bottom panel) in the type 2 diabetic
subjects with diabetic nephropathy (T2DM DN) (dashed bars), the
type 2 diabetic subjects without nephropathy (T2DM DN-) (dotted
bars) and in non diabetic control subjects (empty bars).
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netic variants of the lipoprotein lipase can be involved too
(27). DNA single nucleotide polymorphisms and three
common exonic mutations were found to be differentially
expressed in T2DM subjects with nephropathy, as com-
pared to normoalbuminuric T2DMsubjects (27). Follow-
ing logistic regression analysis, the P(2)P(2) genotype was
independently associated with the presence of microalbu-
minuria/proteinuria, in addition to systolic bloodpressure
(BP) and plasma creatinine.
Another possible factors could be represented by en-
dothelial damage, and the associated decreased availabil-
ity of the lipoprotein lipase (26, 28). Heparin-releasable
lipoprotein lipase (LPL) mass was significantly lower in
microalbuminuric than in the normoalbuminuric subjects
with T2DM, whereas plasma vWF, a marker for endo-
thelial damage, was greater in microalbuminuric than in
the normoalbuminuric subjects (28). Furthermore, LPL
masswas inversely correlatedwith plasma vWF level (28).
Finally, proteinuria-associated urinary loss of lipopro-
tein lipase activators, due to increased glomerular base-
ment membrane permeability, had been suggested as a
cause for hyperlipidemia (29).
Taken together, these previously-published, as well as
our present data, support the hypothesis of a reduced re-
moval of triglyceride-rich lipoproteins, possibly mediated
by a reduction in lipoprotein lipase activity, as the main
cause of the hypertriglyceridemia in T2DM subjects with
nephropathy. Our kinetic data are consistent with previ-
ous work based on measurements of LPL activity, release
or circulating mass.
The possible role of insulin resistance should also be
discussed. Subjects with type 2 diabetes and nephropathy
(ie, with albuminuria) have been reported to be more in-
sulin resistant than subjects without nephropathy (30,
31). Insulin-resistance should lead to an increased hepatic
apolipoprotein B-100 production and/or release, due to
the loss of the inhibitory effect of insulin on its production
(32). In this respect, in T2DM an increased liver produc-
tion in association with insulin resistance has been re-
ported for fibrinogen, ie, another liver-synthesized pro-
teins (6), but not for albumin (33). In contrast, as regards
VLDL-Apo B 100 kinetics, our data are not consistent
with a role of insulin resistance onApoB 100metabolism,
since the VLDL-Apo B 100 fractional production rate in
the T2DM subjects with nephropathy was actually de-
creased,by50%with respect to thatobserved in subjects
with T2DMbut without nephropathy (Table 2, Figure 2).
HDL cholesterol was decreased in the subjects with
T2DM and nephropathy. Although we didn’t measured
Apo A synthesis, in a previous study Apo A1 fractional
catabolism rate was increased in T2DM (34), thus indi-
cating a mechanism for the decreased Apo A1
concentration.
Although the T2DM subjects with DNwere 14 and 11
yrs older than either the T2DM DN- or the non diabetic
control subjects, respectively, and were also slightly
heavier (Table 1), these differences were not statistically
significant. Nevertheless, we would exclude any impor-
tant effect of these variations in the main results of the
study. As a matter of fact, we didn’t find any correlation
between either age or BMI, and VLDL-Apo B 100 FSR
(P .4, data not reported). In addition, inclusion of either
age or BMI as covariates did not abolish the differences of
VLDL-Apo B 100 FSR between the T2DM with DN and
the two other groups (data not shown). In any case, vis-
ceral obesity, if anything, would rather lead to an increase
(not to a decrease) of VLDLApo B synthesis/secretion, on
the basis of observations performed in nondiabetic people
(35). Age on turn was previously found to be positively
correlated with hepatic VLDL Apo B secretion (36–38).
As a matter of fact, the greater age and/or BMI values of
the T2DM subjects with nephropathy would have rather
lead to an underestimation of the differences observed in
VLDLApoB100FSRwith respect to that of the twoother
groups.
The results of this study should be discussed also with
respect to therapy. Three categories of drugs are currently
used to treat hypertriglyceridemia in T2DM: fibrates, st-
atins and omega-3 poly-unsaturated fatty acids (PUFA).
Fibrates are peroxisome-proliferator-activated receptor
(PPAR)- agonists, they increase the peripheral clearance
of bothVLDL-andLDLapoB-100, and reduceVLDLapo
B-100 production (39). The same mechanisms are sug-
gested as regards statins, due to their cross-talk with
PPAR activators (40), and both inhibition of Apo B 100
production (41) and increase of clearance (42) have been
reported with statins. In contrast, omega-3 PUFA affect
VLDL metabolism mainly by reducing VLDL triacylglyc-
erol secretion (43). In addition, they may increase both
VLDL apoliprotein B degradation (as observed at least in
isolatedhepatocytes) (44), and (possibly but less certainly)
also VLDL clearance, without however affecting the lipo-
protein lipase (45). Generally speaking, at least two of the
usual lipid-lowering drug cathegories are appropriate to
improve the impaired peripheral clearance of VLDL-Apo
B containing particles, with the purpose to reduce plasma
triglycerides.
In our study, only three of the T2DM patients (one in
the normoalbuminuria group, two in the proteinuria
group)were treatedwith ahypolipidemic agent (a fibrate),
despite the fact that the triglyceride concentrations were
not at target in the latter group as a whole. These agents,
as well as other drugs, were withdrawn just the night be-
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fore the study. We recognize that this very short wash out
period could represent a potential bias. Nevertheless, the
individual data of these three subjects fell within 1 SD or
less from the corresponding group’s mean, and exclusion
of these subjects did not change the overall results (data
not shown). Furthermore, since fibrates, as stated above,
should have increased (ie, not decreased) VLDL-Apo B
clearance, their effect should actually have led to an un-
derestimation of the (lowest) values of Apo B clearance in
the diabetic group with proteinuria.
As regards the possible role of the hypoglycemic ther-
apy, the T2DM patients with DN were more extensively
treated with insulin than those without DN (see: Meth-
ods). Since insulin has been reported to decrease Apo B
assembly and secretion (46), insulin treatment in the
T2DMDN subjects might have contributed to suppres-
sion of hepatic VLDL-Apo B 100 production. However,
the (peripheral) insulin concentrations between the
T2DM subjects with and without DN were nearly iden-
tical (Table 1), whereas the two groups were clearly dif-
ferent as regards VLDL-Apo B 100 production. In addi-
tion, OHA therapy (more extensively used in the T2DM
subjects without nephropathy) should stimulate endoge-
nous insulin secretion, thus creating a portal-hepatic vein
insulin gradient that, in the presence of comparable pe-
ripheral insulin levels, would suggest a greater portal vein
insulin concentrations in the OHA vs. the insulin-treated
subjects, with a greater effect on the liver. Nevertheless,
the T2DM subjects without DN had a greater VLDL-Apo
B 100 production than those with DN (Figure 2). Taken
together, these observations would exclude a significant
effect of the type of hypoglycemic therapy too on themain
findings of this study.
Although the severity of nephropathy variedwithin the
T2DM patients with DN, five of them being in the ne-
phrotic range, the creatinine concentrations on average
were (modestly) increased in this group, and only in one
subjects it was greater than 300 M. Nevertheless, a pos-
sible effect of renal insufficiency itself in the observed find-
ings might strictly not be excluded.
In conclusion, the data of this study indicate a patho-
physiological mechanism (ie, a decreased VLDL-Apo B
100 removal) to account for the hypertrygliceridemia of
T2DMsubjectswith diabetic nephropathy, and therefore,
they provide a rationale for current treatment protocols
aimed at the correction of triglyceridemia in this
condition.
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